Find Clinical Trial

A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study.


← Back
Study Phase

Phase 2

Therapeutic Area

Immune-Inflammatory Diseases

IndicationSjögren’s Syndrome
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S95011

Active Substance CodeS95011
Protocol CodeCL2-95011-001
EudraCT Code2020-001526-59
NCT CodeNCT04605978




Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2020 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility